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Few preventative or therapeutic measures for CS-AKI exist, and standard care is supportive, requiring fluid restriction, diuresis, and avoidance of nephrotoxins. Given the association between CS-AKI and outcome after pediatric cardiac surgery, efforts aimed at modifying CS-AKI risk may yield important reductions in postoperative mortality and cardiac ICU and hospital length of stay (LOS). Though some factors may be modifiable, efforts to identify practices to reduce CS-AKI rates and improve patient outcomes are ongoing.
Tight glycemic control (TGC) showed promise as a therapy to prevent CS-AKI. Retrospective data suggest an association between intraoperative hyperglycemia and CS-AKI (9) for adult surgical patients. Two prior clinical trials demonstrated a reduction in renal replacement therapy and new acute kidney injury (AKI) in critically ill adults randomized to TGC in surgical and medical ICUs (10, 11) . Multiple studies have explored associations between hyperglycemia, renal dysfunction, and clinical outcome with conflicting results (10) (11) (12) (13) (14) (15) . The Safe Pediatric Euglycemia after Cardiac Surgery (SPECS) study demonstrated no benefit of TGC on healthcare-associated infection (HAI) rates in the overall study cohort, but the relationship between TGC and CS-AKI in this population has not been explored (12) .
To characterize the relationship between TGC and CS-AKI, we performed a planned secondary analysis of the SPECS trial, in which children were randomized to TGC versus standard care in the postoperative period after cardiac surgery. We hypothesized that patients in the TGC group would have lower CS-AKI risk. Also, we sought to explore center variation in CS-AKI epidemiology, including differences in CS-AKI and associated clinical outcomes.
MATERIALS AND METHODS
Details of the SPECS trial were published previously (12, 16) . In brief, 980 children less than 36 months old undergoing cardiac surgery requiring CPB at University of Michigan (UM), C.S. Mott Children's Hospital, and Boston Children's Hospital (BCH) were enrolled from September 2006 to May 2012. Children were randomized to receive TGC (80-110 mg/ dL) or standard care postoperatively. Bedside clinicians were not blinded to treatment group assignments. The trial's primary outcome was the rate of HAI, including bloodstream infections, urinary tract infections, pneumonia, and surgical site infections. TGC did not reduce the rate of HAI compared with standard care (12 ; p = 0.03). The original study was approved by the institutional review board (IRB) at both institutions, and parents or legal guardians gave written informed consent.
The current study is a planned secondary analysis of existing SPECS data. Additional laboratory data not part of the study database were extracted from the hospitals' medical record, including preoperative (baseline) and daily highest postoperative creatinine levels and use of modified ultrafiltration (MUF). All patients with the requisite serum creatinine data to assign postoperative CS-AKI were included. Preoperative AKI and remote AKI history were not assessed in the parent study, so AKI status prior to randomization is unknown. IRB approval was obtained for collection of additional study variables and retrospective review of data from the original study.
CS-AKI was assigned using the AKI Network (AKIN) criteria, which was the most frequently used AKI classification system at the time of study design (17) : stage I (mild CS-AKI) was defined as an increase in serum creatinine from baseline by greater than or equal to 0.3 mg/dL or 150-199%, stage II (moderate CS-AKI) as an increase from baseline by 200-299%, and stage III (severe CS-AKI) as an increase from baseline by greater than or equal to 300%, a serum creatinine of greater than or equal to 4.0 mg/dL or need for renal replacement therapy. Due to the relatively low serum creatinine levels in our population, we modified the AKIN criteria to require an increase in serum creatinine from baseline of greater than 0.1 mg/dL to assign CS-AKI of any stage. This was performed in order to prevent small variations in serum creatinine from overestimating the true frequency of CS-AKI (e.g., a rise in serum creatinine from 0.2 to 0.3 mg/dL, which, using the AKIN criteria, would be considered as stage I AKI) (17) . Accurate urine output data were unavailable and not used to assign CS-AKI. CS-AKI duration was defined as time to normalization of serum creatinine to baseline. Surgical complexity was assessed using the Risk Adjustment in Congenital Heart Surgery (RACHS)-1 (18) score as this was the most common case-mix adjustment method used when the trial protocol was developed.
Treatment group comparisons of CS-AKI frequency, CS-AKI stage, first day of CS-AKI, and CS-AKI duration were made using Fisher exact tests or Wilcoxon rank-sum tests. We found no statistically significant differences in LOS or mortality outcomes between stage I patients and stage II or III patients (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/PCC/A456), so patients with any CS-AKI were combined into one group and compared with patients with no CS-AKI in most analyses. Univariable logistic regression was used to compare patient characteristics between children with and without CS-AKI. Stepwise multivariable logistic regression with adjustment for treatment group and site was performed to predict CS-AKI incidence. Additional predictors were defined a priori and included age at surgery, weight-forage z score, gender, prematurity, RACHS-1 category greater than or equal to 3 or not assignable, single ventricle physiology, CPB time greater than or equal to 120 minutes, cross-clamp time greater than or equal to 60 minutes, use of deep hypothermic circulatory arrest, highest intraoperative glucose greater than or equal to 250 mg/dL, use of intraoperative steroids, and delayed sternal closure (postoperative characteristics were not considered). MUF was considered but was found to be highly collinear with site, so could not be evaluated as an independent predictor.
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A p value of less than 0.05 was required for a covariate to remain in the model. Kaplan-Meier curves and proportional hazards regression with adjustment for site were used to evaluate the impact of CS-AKI frequency and duration (0, 1, 2, or ≥ 3 d) on the outcomes of duration of mechanical ventilation and cardiac ICU and hospital LOS, and logistic regression with adjustment for site was used for in-hospital mortality. CS-AKI duration was categorized due to the rapid onset and resolution in the population, with shorter CS-AKI duration hypothesized to be associated with less adverse outcomes. Outcomes longer than 30 days were censored at day 30. Multivariable proportional hazards regression was used to further evaluate the effect of CS-AKI on the LOS outcomes after controlling for other factors known to be associated with worse outcomes. Site comparisons of CS-AKI frequency, CS-AKI stage, first day of CS-AKI, CS-AKI duration, and patient characteristics were made using Fisher exact tests or Wilcoxon rank-sum tests. Analyses were performed using SAS (version 9.4; SAS Institute, Cary, NC).
RESULTS

Patient and Clinical Characteristics
Among the 980 patients enrolled in the SPECS study, 799 patients (82%) had the requisite serum creatinine measurements to determine CS-AKI status and were included in this study. Excluded patients were older (8.1 vs 4.2 mo; p < 0.001) and had less complex surgeries (RACHS-1 category ≥ 3 or not assignable, 32% vs 57% and single ventricle, 10% vs 22%; p < 0.001 for both). Patients were similar with respect to sex, prematurity, chromosomal or noncardiac anomalies, and cross-clamp time. The missing data rate was similar between treatment groups (TGC, 19% vs standard care, 18%; p = 0.51). The TGC group accounted for 49% of the cohort (n = 395/799); UM patients numbered 327 (41%).
CS-AKI Epidemiology
CS-AKI occurred in 289 patients (36%). Stage I occurred in 28% with CS-AKI (n = 80/289), stage II ocurred in 47% (n = 137/289), and stage III ocurred in 25% (n = 72/289). The median CS-AKI duration was 2 days, with most (83%) developing CS-AKI on postoperative day 1.
Any CS-AKI (36% vs 36%; p = 0.99) and stage II/III CS-AKI rates (28% vs 25%; p = 0.38) were similar between treatment groups. CS-AKI lasted a median duration of 2 days (IQR, 1-3) for both treatment groups (p = 0.35), but patients in the TGC group developed CS-AKI on postoperative day 1 more frequently (89% vs 78%; p = 0.02). Adjustment for site did not change treatment group comparisons, nor were there any significant treatment groups by site interactions. CS-AKI rates were similar between treatment groups at each site (TGC vs standard care; UM: 66% vs 66%, p = 0.91; BCH: 15% vs 16%, p = 0.70). Table 1 shows univariable associations. Patients were similar with respect to prematurity, previous cardiac surgery, and chromosomal and noncardiac anomalies. CS-AKI patients underwent more complex surgery (p < 0.001) with shorter cross-clamp times (p = 0.02) and more frequent use of hypothermic circulatory arrest (p = 0.004). Few patients (n = 11) required renal replacement therapy (Table 1) . CS-AKI patients had more frequent intraoperative hyperglycemia (blood glucose ≥ 250 mg/dL), MUF, and delayed sternal closure and were less likely to have had intraoperative steroids (p < 0.001 for each). There was no difference in time-weighted blood glucose average or hypoglycemia rates between patients with CS-AKI and those without.
Using multivariable analysis, younger age, RACHS-1 greater than or equal to 3 or not assignable, CPB time greater than or equal to 120 minutes, and site predicted CS-AKI ( Table 2) . Site was the most important contributor to the model with an odds ratio of 15.8 (p < 0.001). Treatment group was not a significant predictor of CS-AKI, nor was there a significant treatment group by site interaction.
Clinical Outcomes Related to CS-AKI
In site-adjusted analysis, CS-AKI patients experienced higher mortality (7% vs <1%; p < 0.001) and had longer mechanical ventilation and cardiac ICU and hospital LOS ( Table 3) . After adjustment for other factors associated with worse outcomes, including age, cardiac support time, surgical complexity, delayed sternal closure, need for extracorporeal membrane oxygenation, and unanticipated reoperation, CS-AKI was associated with longer mechanical ventilation (median, 4 vs 2 d), cardiac ICU LOS (5.6 vs 2.8 d), and hospital LOS (12 vs 7 d; p < 0.001 for each). Further, duration of CS-AKI predicted prolonged mechanical ventilation, cardiac ICU LOS ( Figs. 1 and  2) , and hospital LOS. We found no association between TGC and these secondary outcomes in the multivariable analysis.
Site Differences
Site strongly predicted CS-AKI ( Table 4) . Both any CS-AKI (66% vs 15%) and moderate-to-severe CS-AKI (51% vs 9%; p < 0.001 for both) were greater at UM. Median CS-AKI duration was 2 days (IQR, 1-3) at both sites. In general, CS-AKI occurred by postoperative day 2 at both sites, though UM patients developed CS-AKI on postoperative day 1 more frequently. CS-AKI occurred on postoperative day 1 in 241 patients; 93% of UM patients and 83% of BCH patients reached maximum CS-AKI stage on this day.
UM patients were more likely to have single ventricle physiology (28% vs 17%; p < 0.001), but preoperative characteristics were otherwise similar (Supplemental Table 2 , Supplemental Digital Content 2, http://links.lww.com/PCC/A457). Patients at UM had shorter cardiac support times (CPB time ≥ 120 min, 27% vs 50%; cross-clamp time ≥ 60 min, 27% vs 64%), more intraoperative hyperglycemia (33% vs 8%), lower intraoperative steroids use (19% vs 74%), and more frequent MUF (91% vs 8%) (p < 0.001 for each).
We found that CS-AKI affected clinical outcome at each site differently ( Table 5) Premature birth, n (%) 91 (18) 50 (17) 12 (15) 38 (18) 0.85
Chromosomal anomaly, n (%) 96 (19) 62 (21) 20 (25) 42 (20) 0.37
Noncardiac structural abnormality, n (%) 66 (13) 39 (13) 11 (14) 28 ( 
DISCUSSION
In this planned secondary analysis of 799 patients from the SPECS trial (12, 16), we found that CS-AKI occurred in 36% patients with most (72%) having stage II or III disease. To our knowledge, this is the first study examining the relationship between TGC and pediatric CS-AKI. Although previous studies in adults suggested a protective effect of TGC (9-11), we found no association between TGC and CS-AKI. Consistent with previous work, we observed worse clinical outcomes in CS-AKI patients. However, we did observe striking differences in CS-AKI rates and differential impact on clinical outcomes across the two study sites. Though investigators have reported disparate CS-AKI rates following congenital heart surgery (1-5), there are no prior data on site differences within the relatively homogenous populations using a standard data collection method. Our study allows some investigation into potentially modifiable practice variations. Although we identified some site-specific practice variations (e.g., use of MUF, intraoperative steroids) that may contribute to CS-AKI, we found that site and MUF were collinear with highly discrepant MUF rates (UM, 91% vs BCH, 8%) Hypoglycemia (< 60 mg/dL), n (%) 66 (13) 50 (17) 16 (20) 34 ( precluding evaluating MUF in the multivariable analysis. The role of ultrafiltration on CS-AKI has not been fully explored to date. Paugh et al (19) found that patients receiving intraoperative continuous ultrafiltration had higher AKI rates, with increasing fluid removal associated with more AKI in patients with pre-existing renal dysfunction. Kuntz et al (20) showed no relationship between intraoperative ultrafiltration and intraoperative urinary flow rate, but the study did not define AKI using classification systems. Given that infants have late renal maturation, volume shifts associated with MUF may confer additional CS-AKI risk.
In part, MUF usage may explain the discrepant CS-AKI rates, CS-AKI timing, and the transient CS-AKI we observed. We postulate that early transient CS-AKI may indicate that MUF predisposes vulnerable patients to CS-AKI. Another plausible explanation is that the early postoperative rise in serum creatinine reflects MUF-related volume depletion and does not reflect true injury. At UM, MUF is commonly used following CPB, which predictably resulted in rising serum creatinine within the first 24 postoperative hours. Potential additional factors contributing to the difference in CS-AKI frequency include intraoperative and postoperative intravascular volume status, CPB strategy, postoperative fluid administration, residual heart disease, blood loss, and total blood product administration (21) (22) (23) . For example, excessive fluid overload (which was unmeasured in our study) may result in prolonged mechanical ventilation and LOS, but which may be modified by MUF, reducing the impact of CS-AKI on those outcomes. We postulate that some of these unmeasured variables are contributory to the CS-AKI site difference we found. Future work aimed at using novel biomarkers and uncovering more granular intraoperative and postoperative practices will undoubtedly help us understand why CS-AKI affects clinical outcomes differently at different cardiovascular programs.
Despite finding higher CS-AKI rates at UM, UM CS-AKI patients had shorter mechanical ventilation and cardiac ICU and hospital LOS compared with BCH CS-AKI patients. Although CS-AKI itself may be an important morbidity, the site-specific impact on other clinical outcomes appears variable. Furthermore, this discrepancy between higher CS-AKI rates and shorter mechanical ventilation and LOS at UM suggests that not all CS-AKI is created equal. Multiple studies have described discrepant CS-AKI rates and outcome associations (1-4, 7) . Our data lend credence to the hypothesis that MUF-related early increases in serum creatinine may represent volume shifts rather than glomerular or interstitial injury. Although these patients met qualifications for AKI using creatinine-based criteria, this may not represent true kidney injury. To further investigate this hypothesis, it will be important to corroborate these findings by pairing serum creatinine-based AKI definitions with AKI biomarkers in future studies. Patients Multivariable models adjust for treatment group, site, age at surgery, weight-for-age z score, female gender, premature birth, chromosomal anomaly, noncardiac structural abnormality, Risk Adjustment in Congenital Heart Surgery-1 category ≥ 3 or not assignable, cardiopulmonary bypass time ≥ 120 min, cross-clamp time ≥ 60 min, delayed sternal closure, unanticipated reoperation, cardiopulmonary resuscitation, extracorporeal membrane oxygenation, packed RBC transfusion on postoperative day 1, and hypoglycemia (blood glucose < 60 mg/dL).
b A hazard ratio < 1 indicates that acute kidney injury is associated with a longer duration of mechanical ventilation, cardiac ICU stay, or hospital stay. receiving MUF with a small serum creatinine rise 24 hours after surgery may have biomarker negative AKI (creatinine rise without damage), potentially explaining the divergent outcomes at both sites. Pediatric CS-AKI rates vary widely from 15% to 52%, much of which is limited to mild disease, with investigators previously demonstrating no association between mild CS-AKI and outcome (12, 13) . Our outcome data, however, are more consistent with adult data, which found that critically ill postsurgical patients with mild AKI are at risk for poor outcomes (6) . The reasons underlying our discrepant findings are unclear but may be due to differing patient demographics, as well as unmeasured institutional practice (1-4). Taylor et al (3) reported on a large, heterogeneously aged cohort with significantly lower rates of CS-AKI and without an effect of mild CS-AKI on postoperative outcome. Though previous work described significant differences in outcome with increasing CS-AKI severity, we did not observe this phenomenon, which suggests that center-specific variables may modulate its effect on outcome. Previous work in pediatric CS-AKI has not assessed the effect of CS-AKI duration on outcome. We found that CS-AKI developed quickly after surgery (< 2 d) with rapid resolution, indicating transient injury. The early onset and short CS-AKI duration may indicate that intraoperative and postoperative volume status may be an important and, as yet, unmeasured determinant of CS-AKI. In particular, ultrafiltration results in intravascular volume contraction following CPB and has been associated with CS-AKI in adults (20) . Postoperative hypovolemia may result in rapidly resolving CS-AKI, whereas more prolonged CS-AKI may have a different etiology. Patients with transient moderate-to-severe CS-AKI may not be significantly different from those with mild CS-AKI. Patients with shorter CS-AKI had shorter mechanical ventilation and cardiac ICU and hospital stays compared with those with longer CS-AKI duration. CS-AKI duration may be another useful measure to determine the clinical burden of CS-AKI, and measures aimed at reducing CS-AKI duration (e.g., reducing early nephrotoxin exposure or early reintervention for residual heart disease) may improve outcomes. More durable CS-AKI may suggest prolonged exposure to residual heart disease, which may leave the kidney exposed to high central venous pressures and limited renal blood flow for a prolonged time. Earlier reintervention to ameliorate deleterious hemodynamics may reduce clinical impact of CS-AKI.
Consistent with previous work, we found that younger age, higher RACHS-1 category, and longer bypass time were associated with CS-AKI. Similarly, multivariable modeling demonstrated that CS-AKI was associated with prolonged mechanical ventilation and cardiac ICU and hospital LOS. Patients with stage I CS-AKI were similar to patients with stages II and III with respect to mechanical ventilation and postoperative cardiac ICU and hospital LOS. We discovered important differences in CS-AKI rates and differential impact on clinical outcomes across the two surgical sites.
Our study has several limitations. First, we performed an analysis from an existing prospectively collected database, limiting our ability to control for important covariates (e.g., postoperative blood loss, fluid overload, CPB strategy, and deleterious hemodynamics) that were not included in the data collection. Further, previous AKI and chronic kidney disease history were not obtained in the parent trial, and we were unable to include those data in our analysis. Second, we cannot prove that CS-AKI or CS-AKI duration is causal with regard to poor outcomes. We modified the AKIN criteria to require a serum creatinine rise of greater than 0.1 mg/dL to prevent overdiagnosis of CS-AKI. Such a small change in creatinine may be within laboratory error, so we would have likely overestimated CS-AKI, particularly in infants and small children. Third, given the disparate CS-AKI rates at the two sites, we could not account for site-specific practices regarding postoperative cardiac ICU care that may explain these findings. Fourth, our analysis excluded 181 patients without available serum creatinine data. The excluded patients were older and underwent less complex operations, so we may be overestimating CS-AKI. Fifth, although available, serum creatinine is a limited CS-AKI biomarker and may not sufficiently distinguish clinically important from less clinically relevant CS-AKI. Novel AKI biomarkers may help us understand CS-AKI mechanisms more specifically than serum creatinine (5). Basu et al (24) demonstrated that correcting serum creatinine or fluid overload may help distinguish clinically significant CS-AKI in some patients previously classified as having less severe CS-AKI. Furthermore, data with respect to intraoperative and postoperative fluid overload status were not collected. Excessive fluid overload may require prolonged mechanical ventilation and may necessitate fluid restriction, which may limit the provision of nutrition. Finally, we could not use urine output to define CS-AKI as the data were unavailable, possibly leading to underestimation of moderate-to-severe CS-AKI. Previous work has found that urine output criteria may increase the detectable rate of moderate-to-severe CS-AKI than using serum creatinine criteria alone (2).
CONCLUSIONS
We found no evidence to support the use of TGC to prevent CS-AKI. Our analyses revealed novel, provocative findings related to center-specific differences in CS-AKI rates and a variable impact of CS-AKI on important clinical outcomes across sites. Using the Pediatric Cardiac Critical Care Consortium database, efforts are underway to characterize which modifiable candidate variables may affect CS-AKI, including MUF volume, bypass strategies, blood product utilization, and fluid overload (J.J.B., M.G.) (25) . These data will inform prospective multi-institutional research to determine all relevant covariates, to support future therapeutic trials aimed at reducing the CS-AKI burden on this vulnerable population.
